Goldman Sachs has downgraded Apellis Pharmaceuticals Inc (APLS) to Sell from Neutral as of September 25, 2025. The current price stands at $19.51.
This move underscores increased caution regarding the company's outlook. The downgrade may reflect concerns about competitive pressures, market conditions, or execution risks that could impact Apellis's performance.
Apellis Pharmaceuticals, headquartered in Waltham, Massachusetts, is a commercial-stage biopharmaceutical company focused on developing novel therapeutic compounds for diseases with high unmet needs. Its approved treatments include SYFOVRE, for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI for paroxysmal nocturnal hemoglobinuria.
The company's market capitalization is $2.5 billion, with a P/E ratio of 54.90 and an EPS of 0.30. Upcoming earnings are expected on July 29, 2026, with an estimated EPS of -0.33 and revenue of $214.0 million.
Analyst ratings are one of many factors investors should consider. Currently, the consensus rating for Apellis is Buy, with 7 Strong Buy, 12 Buy, 7 Hold, 1 Sell, and no Strong Sell ratings among 27 analysts.